Could a cheap blood thinner cut stroke risk in africa?
NCT ID NCT06919835
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug cilostazol can prevent recurrent strokes and heart problems in 1100 recent stroke survivors in Ghana. Participants take either cilostazol or a placebo twice daily for 24 months. The goal is to see if this affordable drug, already used in Asia, can reduce major cardiovascular events in a high-risk African population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cilostazol (a blood-thinning drug that helps prevent blood clots)
What this could lead to
If it works, this could provide an affordable and effective way to prevent recurrent strokes in low-resource settings like sub-Saharan Africa.
What could go wrong
This trial is still recruiting and results are not yet available. Previous promising data came mainly from Asian populations, so it may not work as well in Africans. Side effects like bleeding are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Kwame Nkrumah University of Science & Technology
Kumasi, Ghana
Contact Phone: •••-•••-•••• Email: •••••@•••••